News Releases

October 2019

October 21, 2019 10/21/2019 Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFα Therapies in Biologic-Naïve Patients with UC or CD

October 15, 2019 10/15/2019 TAKEDA AGREES TO DIVEST SELECT OTC AND NON-CORE ASSETS TO ACINO FOR OVER $200 MILLION USD

September 2019

September 26, 2019 9/26/2019 New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1

September 25, 2019 9/25/2019 First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab

September 25, 2019 9/25/2019 New England Journal of Medicine Publishes Results of a Phase 2 Trial Evaluating Takeda’s TAK-620 (Maribavir) as a Potential Treatment of Cytomegalovirus (CMV) Infection

September 20, 2019 9/20/2019 Takeda and Lundbeck announce Ministry of Health, Labour and Welfare (MHLW) approval of Trintellix® in Japan

September 19, 2019 9/19/2019 Takeda Recognized in the 2019 Dow Jones Sustainability World Index

September 5, 2019 9/5/2019 Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate

August 2019

August 8, 2019 8/8/2019 Takeda Submits New Drug Application for a Subcutaneous Formulation of Vedolizumab for Patients with Moderately to Severely Active Ulcerative Colitis in Japan

・For legacy Shire information, click here